Reduction in Peripheral CD19+CD24hCD27+ B Cell Frequency Predicts Favourable Clinical Course in XELOX-Treated Patients with Advanced Gastric Cancer | Zendy

Wei Li | Zendy; Dongli Song | Zendy; Hong Li | Zendy; Li Liang | Zendy; Naiqing Zhao | Zendy; Tianshu Liu | Zendy

Open Access

Reduction in Peripheral CD19+CD24hCD27+ B Cell Frequency Predicts Favourable Clinical Course in XELOX-Treated Patients with Advanced Gastric Cancer

Author(s) -

Wei Li,

Dongli Song,

Hong Li,

Li Liang,

Naiqing Zhao,

Tianshu Liu

Publication year - 2017

Publication title -

cellular physiology and biochemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.486

H-Index - 87

eISSN - 1421-9778

pISSN - 1015-8987

DOI - 10.1159/000475435

Subject(s) - medicine , capecitabine , oxaliplatin , gastroenterology , cd19 , cancer , chemotherapy , oncology , adverse effect , clinical endpoint , clinical trial , colorectal cancer , peripheral blood

Accumulating evidence suggests that regulatory B cells (Bregs) play an important role in modulating the immune response to tumours. Our previous study indicated that a small percentage of peripheral CD19+CD24hCD27+ Breg cells slowed gastric cancer progression in XELOX-treated patients. Here, we further investigated the relationship between dynamic changes in circulating Breg cells and the clinical course in XELOX-treated gastric cancer patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research